TREM2, originally identified as a myeloid receptor sustaining microglial response in Alzheimer's disease, has garnered attention in recent years due to its documented expression in various tumors, including breast cancer, ovarian cancer, colon cancer, and sarcoma 46. Here, TREM2 is linked to early-onset autosomal dominant Alzheimer disease.